Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1801P - Impact of intensified androgen deprivation therapy (ADTi) in the metastatic castration-sensitive prostate cancer (mCSPC) setting on metastatic castration-resistant prostate cancer (mCRPC) disease characteristics and survival outcomes

Date

21 Oct 2023

Session

Poster session 14

Topics

Tumour Site

Prostate Cancer

Presenters

Nishita Tripathi

Citation

Annals of Oncology (2023) 34 (suppl_2): S954-S1000. 10.1016/S0923-7534(23)01946-4

Authors

N. Tripathi1, G. Gebrael1, N. Sayegh1, D. Goel1, J. Brundage2, B. Nordblad2, A. Srivastava2, E. Dal1, C. Hage Chehade1, B. Chigarira3, V. Mathew Thomas4, K. Sahu1, B.L. Maughan1, N. Agarwal5, U. Swami2

Author affiliations

  • 1 Medical Oncology / Internal Medicine, University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 2 Medical Oncology / Internal Medicine, University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake city/US
  • 3 Medical Oncology/ Internal Medicine Dept., University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 4 Medical Oncology/internal Medicine, University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 5 Medical Oncology / Internal Medicine Dept., University of Utah Health - Huntsman Cancer Institute, 84112 - Salt Lake city/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1801P

Background

ADTi is the standard of care treatment (Rx) for mCSPC. We hypothesized that pts who received ADTi in mCSPC and progressed to mCRPC would have different disease characteristics and survival than those treated with ADT monotherapy (ADTm) in the mCSPC setting.

Methods

After IRB approval, patient (pt)-level data were collected retrospectively. Eligibility: confirmed diagnosis of mCRPC, treated with 1L approved Rx with follow up data available. Pts were stratified based on whether they received ADTi (docetaxel or novel hormonal therapies) or ADTm in the mCSPC setting. Study endpoints: Progression-free survival (PFS) as and overall survival (OS) from time of mCRPC diagnosis. A multivariate analysis using the Cox proportional hazards model was used adjusting for potential confounders.

Results

519 consecutive pts (368 ADTm and 151 ADTi) seen at our institution between 2009 to 2022 were eligible. mCRPC pts who received ADTi compared to ADTm had lower PSA (10.3 vs. 21.5 ng/ml, P = 0.002), more visceral metastases (20.5 vs. 11.1%, P = 0.005), higher alkaline phosphatase (110.5 vs. 96 U/L, P = 0.034); and had worse median PFS (5.3 vs. 8.6 months, P < 0.001) and OS (21.2 vs. 31.7 months, P < 0.001) compared to those with ADTm in both univariate and multivariate analysis (Table).

Table: 1801P

PFS HR (95% CI, P-value) OS HR (95% CI, P-value)
ADT vs. ADTi (univariate) 0.7 (0.57-0.86, P < 0.001) 0.63 (0.49-0.8, P < 0.001)
ADT vs. ADTi (multivariate) 0.7 (0.53 – 0.91, P = 0.009) 0.69 (0.50 – 0.97, P = 0.03)
Visceral Metastasis 0.73 (0.52 – 1.02, P = 0.062) 0.62 (0.43 – 0.90, P = 0.012)
Log PSA 1.12 (1.06 – 1.18, P < 0.001) 1.13 (1.06 – 1.21, P < 0.001)
Hemoglobin 0.86 (0.80 – 0.92, P < 0.001) 0.87 (0.81 – 0.94, P < 0.001)
Alkaline Phosphatase 1.00 (1.00 – 1.00, P = 0.081) 1 (1.00 – 1.00, P = 0.086)
Gleason Score > 8 0.77 (0.58 – 1.01, P = 0.062) 0.79 (0.57 – 1.09, P = 0.14)

Conclusions

In the era of ADTi for mCSPC, the survival outcomes in the mCRPC is poorer compared to those in the era of ADTm for mCSPC. These hypothesis-generating data may aid patient counseling, prognostication, and clinical trial design in mCRPC in the current era.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

B.L. Maughan: Financial Interests, Personal and Institutional, Advisory Board, paid consultant/advisor to AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bavarian-Nordic (Inst), Clovis (Inst), Genentech (Inst) and BMS (Inst) on his behalf: paid consultant/advisor to AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bav. N. Agarwal: Financial Interests, Personal and Institutional, Advisory Board, Consultancy to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Research funding to Neeraj Agarwal's institution: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, BMS, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon: Consultancy to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle G. U. Swami: Financial Interests, Personal and Institutional, Advisory Board, a consulting or advisory role by Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca, currently or during the past 2 years. Dr. Swami’s institution has received research funding from Janssen, Seattle Genetics/Astellas, and Exelixis, currently or within the past 2 years: a consulting or advisory role by Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca, currently or during the past 2 years. Dr. Swami’s institution has received research funding from Janssen, Seattle Genetics/Astellas, and Exelixis, curren. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.